State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

Christine E Ryan; Inhye E Ahn; Aswin Sekar; Andrew Rawstron; Julia Almeida; Iñaki Martin-Subero; Erin M Parry; Miguel Alcoceba; Dinis P Calado; Alberto Orfao; Anton W Langerak; Hendrik Veelken; Petra Langerbeins; Deborah M Stephens; Sameer A Parikh; Carsten U Niemann; Sandrine Roulland; Kostas Stamatopoulos; Susan L Slager; Tait Shanafelt; Paolo Ghia; Jessica Okosun; Matthew S Davids

doi:10.1038/s41408-025-01341-6

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

Christine E Ryan, Inhye E Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M Parry, Miguel Alcoceba, Dinis P Calado, Alberto Orfao, Anton W Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M Stephens, Sameer A Parikh, Carsten U Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L Slager, Tait ShanafeltPaolo Ghia, Jessica Okosun, Matthew S Davids^*

^*Corresponding author for this work

Department of Haematology

1 Citation (Scopus)

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

Original language	English
Article number	148
Journal	Blood Cancer Journal
Volume	15
Issue number	1
Pages (from-to)	148
ISSN	2044-5385
DOIs	https://doi.org/10.1038/s41408-025-01341-6
Publication status	Published - 29 Aug 2025

Keywords

Humans
Lymphocytosis/therapy
B-Lymphocytes/pathology
Leukemia, Lymphocytic, Chronic, B-Cell/therapy
Disease Progression
Disease Management
Consensus

Access to Document

10.1038/s41408-025-01341-6Licence: CC BY-NC-ND

Cite this

Ryan, C. E., Ahn, I. E., Sekar, A., Rawstron, A., Almeida, J., Martin-Subero, I., Parry, E. M., Alcoceba, M., Calado, D. P., Orfao, A., Langerak, A. W., Veelken, H., Langerbeins, P., Stephens, D. M., Parikh, S. A., Niemann, C. U., Roulland, S., Stamatopoulos, K., Slager, S. L., ... Davids, M. S. (2025). State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. Blood Cancer Journal, 15(1), 148. Article 148. https://doi.org/10.1038/s41408-025-01341-6

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. / Ryan, Christine E; Ahn, Inhye E; Sekar, Aswin et al.
In: Blood Cancer Journal, Vol. 15, No. 1, 148, 29.08.2025, p. 148.

Research output: Contribution to journal › Journal article › Research › peer-review

Ryan, CE, Ahn, IE, Sekar, A, Rawstron, A, Almeida, J, Martin-Subero, I, Parry, EM, Alcoceba, M, Calado, DP, Orfao, A, Langerak, AW, Veelken, H, Langerbeins, P, Stephens, DM, Parikh, SA, Niemann, CU, Roulland, S, Stamatopoulos, K, Slager, SL, Shanafelt, T, Ghia, P, Okosun, J & Davids, MS 2025, 'State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee', Blood Cancer Journal, vol. 15, no. 1, 148, pp. 148. https://doi.org/10.1038/s41408-025-01341-6

@article{f1ed2923ee874583b2b287f4fc3d9b64,

title = "State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee",

abstract = "In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.",

keywords = "Humans, Lymphocytosis/therapy, B-Lymphocytes/pathology, Leukemia, Lymphocytic, Chronic, B-Cell/therapy, Disease Progression, Disease Management, Consensus",

author = "Ryan, \{Christine E\} and Ahn, \{Inhye E\} and Aswin Sekar and Andrew Rawstron and Julia Almeida and I{\~n}aki Martin-Subero and Parry, \{Erin M\} and Miguel Alcoceba and Calado, \{Dinis P\} and Alberto Orfao and Langerak, \{Anton W\} and Hendrik Veelken and Petra Langerbeins and Stephens, \{Deborah M\} and Parikh, \{Sameer A\} and Niemann, \{Carsten U\} and Sandrine Roulland and Kostas Stamatopoulos and Slager, \{Susan L\} and Tait Shanafelt and Paolo Ghia and Jessica Okosun and Davids, \{Matthew S\}",

note = "{\textcopyright} 2025. The Author(s).",

year = "2025",

month = aug,

day = "29",

doi = "10.1038/s41408-025-01341-6",

language = "English",

volume = "15",

pages = "148",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL)

T2 - consensus report from the Intercepting Blood Cancers Workshop Committee

AU - Ryan, Christine E

AU - Ahn, Inhye E

AU - Sekar, Aswin

AU - Rawstron, Andrew

AU - Almeida, Julia

AU - Martin-Subero, Iñaki

AU - Parry, Erin M

AU - Alcoceba, Miguel

AU - Calado, Dinis P

AU - Orfao, Alberto

AU - Langerak, Anton W

AU - Veelken, Hendrik

AU - Langerbeins, Petra

AU - Stephens, Deborah M

AU - Parikh, Sameer A

AU - Niemann, Carsten U

AU - Roulland, Sandrine

AU - Stamatopoulos, Kostas

AU - Slager, Susan L

AU - Shanafelt, Tait

AU - Ghia, Paolo

AU - Okosun, Jessica

AU - Davids, Matthew S

PY - 2025/8/29

Y1 - 2025/8/29

N2 - In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

AB - In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

KW - Humans

KW - Lymphocytosis/therapy

KW - B-Lymphocytes/pathology

KW - Leukemia, Lymphocytic, Chronic, B-Cell/therapy

KW - Disease Progression

KW - Disease Management

KW - Consensus

UR - https://www.scopus.com/pages/publications/105014752049

U2 - 10.1038/s41408-025-01341-6

DO - 10.1038/s41408-025-01341-6

M3 - Journal article

C2 - 40883275

SN - 2044-5385

VL - 15

SP - 148

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 148

ER -

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this